Advisors of the Carillon Tower, an investment management firm, has published its second quarter 2021 âCarillon Eagle Mid Cap Growth Fundâ letter to investors – a copy of which can be found downloaded here. Mid-cap stocks extended their recent streak of success into the second quarter, advancing for the fifth consecutive quarter after the sharp decline induced by the early stages of the pandemic. Among the two style indices, the Russell MidcapÂ® Growth Index (up 11.07%) made a strong comeback against its counterpart Russell MidcapÂ® Value Index (up 5.66%), after quite a delay. important in the first trimester. You can check out the top 5 holdings of the fund to get an idea of ââtheir top bets for 2021.
In Carillon Tower Advisers’ Q2 2021 letter to investors, the fund mentioned Guardant Health, Inc. (NASDAQ: GH) and discussed his position on the company. Guardant Health, Inc. is a precision oncology company based in Redwood City, California with a market capitalization of $ 12.6 billion. GH has achieved a return of -2.85% year-to-date, while its 12-month returns are up 24.28%. The stock closed at $ 127.00 per share on September 15, 2021.
Here’s what Carillon Tower Advisers has to say about Guardant Health, Inc. in its Q2 2021 letter to investors:
“Health guardian is an industry leader in the emerging field of liquid biopsy, a modern diagnostic technology that gives clinicians the ability to detect minute levels of cell-free DNA from cancers located in the blood. The company’s shares came under a bit of pressure during the quarter as a number of new companies started to emerge in this area. Despite this, Guardant remains one of the clear leaders in the space, as it has proprietary tests that have some of the best levels of sensitivity and specificity on the market. “
Copyright: nexusplexus / 123RF Stock Photo
Based on our calculations, Guardant Health, Inc. (NASDAQ: GH) was unable to secure a spot on our list of 30 most popular stocks among hedge funds. GH was in 49 hedge fund portfolios at the end of the first half of 2021, compared to 41 funds in the previous quarter. Guardant Health, Inc. (NASDAQ: GH) has generated a return of 1.25% in the past 3 months.
The reputation of hedge funds as savvy investors has been tarnished over the past decade, as their hedged returns could not keep up with the unhedged returns of stock indices. Our research has shown that small cap hedge fund stock selection managed to beat the market by double digits every year between 1999 and 2016, but the margin for outperformance has shrunk in recent years. Nonetheless, we were still able to identify in advance a select group of hedge funds that have outperformed S&P 500 ETFs by 115 percentage points since March 2017 (see details here). We were also able to identify in advance a select group of hedge funds that underperformed the market by 10 percentage points per year between 2006 and 2017. Interestingly, the margin of underperformance of these stocks has increased in recent years. Investors who are long in the market and short on these stocks would have reported more than 27% per year between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.
At Insider Monkey, we scour multiple sources to uncover the next big investing idea. For example, the Federal Reserve has created trillions of dollars electronically to keep interest rates close to zero. We believe this will lead to inflation and raise house prices. So we recommended this real estate to our monthly subscribers to our premium newsletter. We go through lists like the 10 best EV stocks to choose the next Tesla which will offer a 10x return. Even though we only recommend positions in a tiny fraction of the companies we analyze, we check as many stocks as possible. We read letters from hedge fund investors and listen to equity pitches at hedge fund conferences. You can subscribe to our free daily newsletter at our home page.
Disclosure: none. This article was originally published on Monkey initiate.